



Delivering Versatility and Automation for Streamlined Workflows

medRAD® MRXperion
MR Injection System

POWERED BY CORTENIC™ CONNECTIVITY



Expanded Performance and Versatility

Engineered for the demands of the MR suite, the MEDRAD® MRXperion MR Injection System is designed with performance and versatility in mind for seamless integration and workflow optimization within your MR suite.

Components designed to streamline workflows

- + Trusted piston-based technology for precise, consistent fluid delivery with auto-filling and auto-priming
- + Disposables engineered for ease of use and compatibility
- + Optional Barcode Reader for automatic contrast agent documentation*
- + Optional ISI2 module for synchronization with MR scanner*

Broad compatibility and versatility to support various MR suite needs

- + Scanner field strengths up to and including 7 Tesla
- + Broad range of compatible contrast agents†
- + Optional clamp kit for mobile scanner configurations*
- + Supports both single- and multi-dose workflows with available imaging bulk packages

*Some accessories may require additional setup or software purchase.

†For a complete list of compatible contrast agents for use with the MEDRAD® MRXperion MR Injection System, refer to the MRXperion MR Injection System Operation Manual.

ISI2=Imaging Systems Interfaces; MR=magnetic resonance.

Illuminated volume and status indicators

Snap-on/twist-off syringe design

Flexible pivot points for easy positioning

Convenience tray for supplies

Floor pedestal with lockable casters

Flexible pivot points for easy positioning



With Flexibility to Adapt

The MEDRAD® MRXperion MR Injection System is compatible with a broad range of contrast agents in both single-dose vial and bulk package presentations[‡], enabling versatile workflows that fit with the dynamics of your suite.




1 Bottle



1 Spike



Multiple Patients



The **MEDRAD® Imaging Bulk Package Transfer Spike** is indicated for the transfer of Gadavist® (gadobutrol) contrast media as supplied in an approved Imaging Bulk Package presentation to empty, sterile hand syringes and/or empty, sterile syringes on single-use only syringe-based contrast power injection systems indicated for the controlled, automatic venous administration of contrast agents for MR procedures.

[Click to see MEDRAD® IBP Transfer Spike Instructions for Use](#)

[Click to see full Prescribing Information, including Boxed Warning, for Gadavist®](#)

[‡]For a complete list of compatible contrast agents for use with the MEDRAD® MRXperion MR Injection System, refer to the MRXperion MR Injection System Operation Manual.

Gadavist® (gadobutrol) IMPORTANT SAFETY INFORMATION

WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS

Risk Associated with Intrathecal Use

Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. Gadavist is not approved for intrathecal use.

Nephrogenic Systemic Fibrosis

GBCAs increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of Gadavist in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

The risk of NSF appears highest among patients with:

- Chronic, severe kidney disease (GFR <30 mL/min/1.73m²), or
- Acute kidney injury

Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age >60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.

For patients at highest risk for NSF, do not exceed the recommended Gadavist dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.

Please see following page for additional Important Safety Information and Indications for Gadavist®.

Gadavist® (gadobutrol) Important Safety Information and Indications (continued)

IMPORTANT SAFETY INFORMATION

Contraindication and Important Information about Hypersensitivity

Reactions: Gadavist® is contraindicated in patients with history of severe hypersensitivity reactions to Gadavist®. Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory, or cutaneous manifestations, ranging from mild to severe, have occurred following Gadavist® administration. There have been reports of life-threatening and fatal outcomes from these adverse reactions. Before Gadavist® administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and/or allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to Gadavist®.

Acute Respiratory Distress Syndrome (ARDS): ARDS has been reported with Gadavist® and may be characterized by severe hypoxemia requiring oxygen support and mechanical ventilation. Onset can occur within <30 minutes to 24 hours after administration. For patients demonstrating respiratory distress after administration, assess oxygen requirement and monitor for worsening respiratory function.

Gadolinium Retention: Gadolinium is retained for months or years in several organs. Linear GBCAs cause more retention than macrocyclic GBCAs. At equivalent doses, retention varies among the linear agents. Retention is lowest and similar among the macrocyclic GBCAs. Consequences of gadolinium retention in the brain have not been established, but they have been established in the skin and other organs in patients with impaired renal function. While clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. These include patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions. Consider the retention characteristics of the agent and minimize repetitive GBCA studies, when possible.

Acute Kidney Injury: In patients with chronic renal impairment, acute kidney injury sometimes requiring dialysis has been observed with the use of GBCAs. Do not exceed the recommended dose; the risk of acute kidney injury may increase with higher than recommended doses.

Extravasation and Injection Site Reactions: Extravasation into tissues during Gadavist® administration may result in moderate irritation. Ensure catheter and venous patency before injection.

Overestimation of Extent of Malignant Disease in MRI of the Breast:

Gadavist® MRI of the breast overestimated the histologically confirmed extent of malignancy in the diseased breast in up to 50% of the patients.

Low Sensitivity for Significant Arterial Stenosis: The performance of Gadavist® MRA for detecting arterial segments with significant stenosis (>50% renal, >70% supra-aortic) has not been shown to exceed 55%. Therefore, a negative MRA study alone should not be used to rule out significant stenosis.

Adverse Reactions: The most frequent (≥0.5%) adverse reactions associated with Gadavist® in clinical studies were headache (1.7%), nausea (1.2%) and dizziness (0.5%).

INDICATIONS


Gadavist® (gadobutrol) is indicated for:

- Magnetic resonance imaging (MRI) of the central nervous system (CNS) to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity in adult and pediatric patients including term neonates
- MRI of the breast to assess the presence and extent of malignant breast disease in adult patients
- Magnetic resonance angiography (MRA) to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients including term neonates
- Cardiac MRI (CMRI) to assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD)

[Please see Full Prescribing Information for Gadavist®](#)

Consistent and Personalized Care

The MEDRAD® MRXperion MR Injection System offers integrated connectivity and protocol adjustability for delivering reproducible, personalized care.



Integrated connectivity for patient/protocol information and documentation

- + Modality Worklist integration
- + Protocol storage and retrieval
- + Patient, contrast, and injection information sent directly to PACS as a DICOM secondary capture

Protocol control and adjustability for personalized care

- + eGFR and weight-based dosing calculators
- + Test inject, inject delay, and KVO
- + Volume, flow rate, and pressure monitoring with automatic stop when a fault is detected

DICOM=Digital Imaging and Communications in Medicine;
eGFR=estimated glomerular filtration rate; KVO=keep vein open;
PACS=Picture Archiving and Communication System.

With Technology That Works For You

Radiology departments are under pressure to do more with less. Bayer Radiology Software addresses that pressure directly with connected solutions designed to automate, standardize, and continuously improve the way your department works.

STREAMLINE your exams.

Automated Documentation

Reduces manual entry at both ends of the workflow, before the scan and after, automatically routing data to PACS, RIS, and SR.



STANDARDIZE your fleet.

Injector Management

One approved standard, deployed across every injector in your fleet—without device-by-device management.



ANALYZE your performance.

Workflow Solutions //Insights

Surfaces what's happening, why it's happening, how you compare, and what's working—across your entire connected fleet.



**Choose where to start and add what you need.
Every connected solution builds on the ones before it, and the value adds up.**

Powered by Cortenic™ Connectivity

The platform that connects Bayer injectors, institution systems, and workflow software—transforming **four solutions into one connected system.**

- + Connects compatible injectors with Bayer Radiology Software
- + Data anonymized on-site and encrypted at every layer
- + Cybersecurity and resilience built in by design—injectors continue operating through network disruptions so patient care is never interrupted
- + Enables Remote Support and Diagnostics, backed by Bayer's clinical and service experts

Components and Specifications

ORDERING INFORMATION



MRXperion System **MRXP 200**

Disposables

+ Disposable Syringe Kit **XP 65/115 VS**
 + MEDRAD Imaging Bulk Package **GBP TS**
 Transfer Spike

Optional Accessories

+ Barcode Reader **BCR MRXP**
 + ISI2 Module **ISI2**
 + Mobile Clamp Kit **MBL KT**

Connectivity Powered by Cortenic™ available with Solution Plans for MEDRAD® MRXperion MR Injection Systems

- + Remote Connectivity
- + Modality Worklist Integration
- + PACS, RIS, and SR Interface
- + Injector Management
- + Workflow Solutions //Insights
- + Remote Diagnostics + Support

Some accessories may require additional setup or software purchase.

eGFR=estimated glomerular filtration rate;
 ISI2=Imaging Systems Interfaces; MR=magnetic resonance; PACS=Picture Archiving and Communication System; RIS=Radiology Information System; SR=Speech Recognition.

DIMENSIONS

Control Room Unit	Width: 15.12 in (38.40 cm) Height: 10.76 in (27.33 cm)	Depth: 7.94 in (20.17 cm) Weight: 15.8 lb (7.2 kg)
Scan Room Unit	Width: 23.30 in (59.0 cm) Height: 71.40 in (181.0 cm)	Depth: 23.30 in (59.0 cm) Weight: 94 lb (43 kg)
Power Supply	Width: 7.60 in (19.0 cm) Height: 3.40 in (9.0 cm)	Depth: 15.40 in (39.0 cm) Weight: 6 lb (3 kg)

ELECTRICAL


Voltage Requirements	100–240 VAC (50/60 Hz)	120–210 VA
Electrical Leakage	Unit: <100 microamperes Patient: <100 microamperes	Earth: <500 microamperes

SYSTEM CAPABILITIES

Syringe Capacities	Syringe A: 65 mL	Syringe B: 115 mL
Programmable Volume Range (mL)	Syringe A: 0.5 mL to max syringe volume in: + 0.1 mL increments from 0.5 mL to 31 mL + 1 mL increments above 31 mL Syringe B: 1 mL to max syringe volume in 1 mL increments	
Programmable Flow Rate Range (mL/s)	0.01 to 10 mL/s in: + 0.01 mL/s increments between 0.01 mL/s and 3.1 mL/s + 0.1 mL/s increments between 3.1 mL/s and 10 mL/s	
Keep Vein Open (KVO)	6 factory presets of 0.25 mL every 15, 20, 30, 45, 60, or 75 seconds	
Test Inject	Configurable from 0.5 mL to 20 mL in 0.1 mL increments	
Pressure Range (PSI)	6 factory presets from 100 to 325 PSI or 690 to 2440 kPa	
Injection / Post Injection Reminders	Up to 5 programmable reminders of 1 second to 20 minutes in 1 second increments	
Injection Protocol Storage	60 protocols up to 6 phases each	
Injection Hold / Pause	Up to 20 minutes in 1 second increments	
eGFR Calculator	For adults: MDRD, Cockcroft-Gault, Modified Cockcroft-Gault and CKD-EPI methods For children: Bedside Schwartz method	
Weight-based Dosing Calculator	User configurable	
Scanner Field Strength Compatibility	Up to and including 7 Tesla	
Scanner Connectivity	ISI2 (optional module)	
Mounting	Floor pedestal, with included integrated IV pole	

With Solution Plans to Fit Your Needs

Solution Plans for MEDRAD® MRXperion MR Injection Systems are designed to deliver confidence across your MR suite by combining connected software, maintenance services, and clinical support into a scalable, tiered structure built to deliver value at the right level for every institution.




All customers begin with the Base Solution—a **connected** injector

From there, the Essential Solution Plans offers the fundamentals in **connected** support and maintenance services or software

The Comprehensive Solution Plan offers integrated software, advanced services, education and data for the **connected** suite

Delivering Confidence With Bayer

At Bayer, our value goes beyond the injector. It extends across a portfolio that works together so you can focus on what matters most: patient care.



Learn more about MRXperion
and our scalable solution plans
at [MRXperion.com](https://www.mrxperion.com)



OUR VALUE ADDS UP

The Power of **Partnership**
The Impact of **Innovation**
The Confidence of **Bayer**

Bayer reserves the right to modify the specifications and features described herein or to discontinue any product or service identified in this publication at any time without prior notice or obligation. Please contact your authorized Bayer representative for the most current information.

The individuals depicted in this material are actors and not actual health care providers or patients.

Bayer, the Bayer Cross, Gadavist, MEDRAD, MEDRAD MRXperion, MRXperion, and Cortenic are trademarks owned by and/or registered to Bayer in the U.S. and/or other countries. Other trademarks and company names mentioned herein are properties of their respective owners and are used herein solely for informational purposes. No relationship or endorsement should be inferred or implied.

© 2026 Bayer. This material may not be reproduced, displayed, modified or distributed without the express prior written consent of Bayer.

PP-M-MRX-US-0159-1 June 2026



Bayer HealthCare LLC
100 Bayer Boulevard
P.O. Box 915
Whippany, NJ 07981
U.S.A.
Phone: +1-412-767-2400
+1-800-633-7231
Fax: +1-412-767-4120



Manufacturer
Bayer Medical Care Inc.
1 Bayer Drive
Indianola, PA 15051-0780
U.S.A.
Phone: +1-412-767-2400
+1-800-633-7231
Fax: +1-412-767-4120